Concerns about the ALIFE2 trial – Authors’ reply

Siobhan Quenby, Lauren Ewington, Eva Hamulyák, Luuk J. Scheres, Mariëtte Goddijn, Saskia Middeldorp

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Access to Document

@article{f9c8f7fb5db8488e8514b985f9667223,

title = "Concerns about the ALIFE2 trial – Authors{\textquoteright} reply",

author = "Siobhan Quenby and Lauren Ewington and Eva Hamuly{\'a}k and Scheres, {Luuk J.} and Mari{\"e}tte Goddijn and Saskia Middeldorp",

year = "2024",

month = jan,

day = "20",

doi = "https://doi.org/10.1016/S0140-6736(23)02336-X",

language = "English",

volume = "403",

pages = "248",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10423",

}

TY - JOUR

T1 - Concerns about the ALIFE2 trial – Authors’ reply

AU - Quenby, Siobhan

AU - Ewington, Lauren

AU - Hamulyák, Eva

AU - Scheres, Luuk J.

AU - Goddijn, Mariëtte

AU - Middeldorp, Saskia

PY - 2024/1/20

Y1 - 2024/1/20

UR - http://www.scopus.com/inward/record.url?scp=85182781462&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/S0140-6736(23)02336-X

DO - https://doi.org/10.1016/S0140-6736(23)02336-X

M3 - Comment/Letter to the editor

C2 - 38245246

SN - 0140-6736

VL - 403

SP - 248

JO - The Lancet

JF - The Lancet

IS - 10423

ER -